A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and pharmacist workflows to move eligible patients off flat dosing of pembrolizumab.
|Webinars|May 6, 2022
Beyond the OCM: How Are Commercial Payers & Employers Delivering Value-Based Cancer Care? Part 1
Experts from The US Oncology Network discuss the future of value-based cancer care, and what practices can do as the Oncology Care Model expires.
Advertisement
In this webinar from The American Journal of Managed Care®'s Oncology Value Coalition, experts from The US Oncology Network discussed the future of value-based cancer care.
Despite many successes, the Oncology Care Model (OCM) is set to expire in July 2022, with no replacement on the horizon. That doesn't mean the lessons of the OCM will be forgotten, but continuing the quality care efforts will be difficult. How will practices continue team-based care, patient navigation, and other enhanced services?
The speakers were:
- Rhonda Henschel, senior director of payer solutions, The US Oncology Network
- Ben Jones, vice president of government relations and public policy
McKesson Specialty Provider Organization, The US Oncology Network - Stuart Staggs, senior director of strategic programs, The US Oncology Network
- Lalan Wilfong, MD,vice president of payer relations and practice transformation, The US Oncology Network
In segment 1, they discussed lessons learned from the OCM.
Advertisement
Related to this article
At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.
KFF finds 4.3 million Medicare beneficiaries will lose their MA or stand-alone Part D plans at the end of 2026, as PDP options keep shrinking.
At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.
Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.
Advertisement
Advertisement
Trending on AJMC
1
Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial
2
At the Pharmacy, Affordability Connects Policy, Plans, and Patients
3
UAB Works to Deliver Cutting-Edge Cancer Therapies, Reach Every Patient
4
Olanzapine/Samidorphan Tied to Longer Persistence in Schizophrenia
5